DEVELOPMENT AND STUDY OF VACCINE THIOMERSAL-FREE DRUGS
- Authors: Nikolaeva AM1, Gryaznova DV1, Semenova VD1, Pushkareva EV1, Perevozchikov AB1, Sosnina OY.1
-
Affiliations:
- Issue: Vol 31, No 2 (2014)
- Pages: 117-122
- Section: Articles
- URL: https://permmedjournal.ru/PMJ/article/view/3254
- DOI: https://doi.org/10.17816/pmj312117-122
- ID: 3254
Cite item
Full Text
Abstract
Keywords
About the authors
A M Nikolaeva
Email: a.m.nikolaeva@perm.microgen.ru
D V Gryaznova
Email: d.v.gryaznova@perm.microgen.ru
V D Semenova
E V Pushkareva
A B Perevozchikov
Email: a.b.perevozchikov@perm.microgen.ru
O Yu Sosnina
References
- Сопоставимость биотехнологических продуктов, полученных до и после внесения изменений в процесс производства. Общие принципы планирования исследований: методические рекомендации. М.: ФГБУ «ГИСК им. Л. А. Тарасевича» Минздравсоцразвития России 2011; 28.
- Geier M. R., Geier D. A. Neurodevelopmental Disorders Following Thimerosal-Containing Vaccines. Experimental Biology & Medicine 2003; 228: 660-664.
- Geier M. R., Geier D. A. Thimerosal in childhood vaccines, neurodevelopment disorders, and heart disease in the United States. Journal of American Physicians & Surgeons 2003; 8 (1): 6-11.
- Guidelines on regulatory expectations related to the elimination, reduction or replacement of thimerosal in vaccines. WHO. TRS №926; 2004; 4: 95-102.
- Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS). Pediatrics 1999; 104 (3 Pt 1): 568-569.
- Wantke F., Hemmer W., Jarisch R., Gotz M. Patch test reactions in children, adults, and elderly. Contact Dermatitis 1996; 34: 316-319.